Logo image of RZLT

REZOLUTE INC (RZLT) Stock Fundamental Analysis

NASDAQ:RZLT - Nasdaq - US76200L3096 - Common Stock - Currency: USD

3.81  -0.09 (-2.31%)

Fundamental Rating

3

Taking everything into account, RZLT scores 3 out of 10 in our fundamental rating. RZLT was compared to 561 industry peers in the Biotechnology industry. RZLT has a great financial health rating, but its profitability evaluates not so good. RZLT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RZLT had negative earnings in the past year.
RZLT had a negative operating cash flow in the past year.
RZLT had negative earnings in each of the past 5 years.
In the past 5 years RZLT always reported negative operating cash flow.
RZLT Yearly Net Income VS EBIT VS OCF VS FCFRZLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

RZLT's Return On Assets of -63.51% is on the low side compared to the rest of the industry. RZLT is outperformed by 62.39% of its industry peers.
RZLT has a Return On Equity of -71.43%. This is comparable to the rest of the industry: RZLT outperforms 53.30% of its industry peers.
Industry RankSector Rank
ROA -63.51%
ROE -71.43%
ROIC N/A
ROA(3y)-39.29%
ROA(5y)-113.74%
ROE(3y)-50.7%
ROE(5y)-448.92%
ROIC(3y)N/A
ROIC(5y)N/A
RZLT Yearly ROA, ROE, ROICRZLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

RZLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RZLT Yearly Profit, Operating, Gross MarginsRZLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for RZLT has been increased compared to 1 year ago.
Compared to 5 years ago, RZLT has more shares outstanding
There is no outstanding debt for RZLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RZLT Yearly Shares OutstandingRZLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RZLT Yearly Total Debt VS Total AssetsRZLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RZLT has an Altman-Z score of 10.38. This indicates that RZLT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of RZLT (10.38) is better than 87.88% of its industry peers.
There is no outstanding debt for RZLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.38
ROIC/WACCN/A
WACCN/A
RZLT Yearly LT Debt VS Equity VS FCFRZLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 9.30 indicates that RZLT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.30, RZLT is in the better half of the industry, outperforming 77.18% of the companies in the same industry.
A Quick Ratio of 9.30 indicates that RZLT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.30, RZLT is doing good in the industry, outperforming 77.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.3
Quick Ratio 9.3
RZLT Yearly Current Assets VS Current LiabilitesRZLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for RZLT have decreased by -0.88% in the last year.
EPS 1Y (TTM)-0.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RZLT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.26% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.89%
EPS Next 2Y12.19%
EPS Next 3Y9.77%
EPS Next 5Y23.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RZLT Yearly Revenue VS EstimatesRZLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RZLT Yearly EPS VS EstimatesRZLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RZLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RZLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RZLT Price Earnings VS Forward Price EarningsRZLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RZLT Per share dataRZLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.19%
EPS Next 3Y9.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RZLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REZOLUTE INC

NASDAQ:RZLT (5/23/2025, 9:47:04 AM)

3.81

-0.09 (-2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)09-17 2025-09-17/amc
Inst Owners74.05%
Inst Owner Change2.88%
Ins Owners0.86%
Ins Owner Change0.51%
Market Cap325.68M
Analysts86.25
Price Target13.71 (259.84%)
Short Float %4.51%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.4%
Min EPS beat(2)12.17%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)1.19%
Min EPS beat(4)-32.5%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)6.68%
EPS beat(12)10
Avg EPS beat(12)13.69%
EPS beat(16)12
Avg EPS beat(16)12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.42%
PT rev (3m)3.42%
EPS NQ rev (1m)6.21%
EPS NQ rev (3m)5.46%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.27
P/tB 3.27
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.51%
ROE -71.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.29%
ROA(5y)-113.74%
ROE(3y)-50.7%
ROE(5y)-448.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.3
Quick Ratio 9.3
Altman-Z 10.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.59%
EPS Next Y30.89%
EPS Next 2Y12.19%
EPS Next 3Y9.77%
EPS Next 5Y23.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-162.49%
OCF growth 3YN/A
OCF growth 5YN/A